Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ingredient, they are approved for different purposes. Ozempic is primarily used for managing type 2 diabetes, whereas Wegovy is specifically approved for weight loss.

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started a side hustle to afford it.

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease,

The FDA has approved a new indication for semaglutide to lower the risk for worsening kidney disease, kidney failure and cardiovascular death among adults with type 2 diabetes and chronic kidney disease,

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential impact on CKD.

Research identifies key factors affecting semaglutide initiation among obese individuals without diabetes, revealing significant insurance coverage disparities.

Semaglutide, a medication originally designed to treat type 2 diabetes, has recently gained significant attention as a weight loss treatment. It has shown remarkable results in reducing body weight, making it a popular choice for those struggling with obesity or overweight.

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin requirements and aiding weight management.

The U.S. Food and Drug Administration (FDA) has granted approval for an expanded use of Ozempic® (semaglutide) injection, developed by pharmaceutical company Novo Nordisk (NYSE:NVO). The medication is now approved to lessen the risk of kidney disease progression,